US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
The US Food and Drug Administration’s neurology drugs program received a funding boost in fiscal year 2023 to stay abreast of the evolving landscape, despite the controversy over its approval of Alzheimer’s treatments.
The omnibus appropriations bill enacted in December included an additional $2m that lawmakers said was intended for the agency...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
